Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPOPEX
2024-515703-19-00Phase 3Completed
- Sponsor
- DBV Technologies
- Start
- Sep 2024
- Modality
- Transdermal Patches → Device-based Delivery → Drug Delivery Systems
- Countries
- 6
01
Overview
Phase 3, open-label, single-arm trial of DBV712 Viaskin® in peanut allergy, sponsored by DBV Technologies. Started Sep 2024; status: completed.
02
Drugs
DBV712 Viaskin®
03
Conditions
peanut allergy
Beyond the preview
Go deeper on 2024-515703-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515703-19-00.